Pfizer’s Goettler On What Partners Look For In Orphan Drug Deals
Michael Goettler, Pfizer's global president, rare disease global innovative pharma business, offers tips to Korean orphan drug developers on reaching out to potential partners successfully and what Pfizer is looking for in rare disease deals.
You may also be interested in...
In what appears to be the first open innovation-based partnership between leading South Korean pharma firms, GC Pharma and Yuhan have agreed to conduct joint early research on orphan drugs, capitalizing on each others' strengths. The move may herald a shift in domestic companies' views on such collaboration and a possible increase in similar tie-ups, amid their ongoing efforts to pursue innovation.
Amid ongoing interest in accessing innovative assets, including those from South Korea, big pharma participants at a recent symposium in Seoul shared the ins and outs of the complex partnering process.
Pfizer has turned again to external expertise among US biotechs to find a potential gene therapy for hemophilia A, to add to its two-year collaboration with Spark Therapeutics on a gene therapy for hemophilia B, and beating off strong competition from other suitors in the process.